Health
Mirati to contribute $4 million grant to support SU2C research on KRAS mutant cancers – News-Medical.Net
Stand Up To Cancer and Mirati Therapeutics Inc. – a late-stage targeted oncology company – today announced that Mirati will contribute a $4 million grant to SU2C…
Stand Up To Cancer® (SU2C) and Mirati Therapeutics Inc. – a late-stage targeted oncology company – today announced that Mirati will contribute a $4 million grant to SU2C to develop new approaches to treat patients with KRAS mutant cancers, as a part of the SU2C Catalyst® program.
The research will focus on cancer types with unmet medical needs, and the application of tumor-agnostic strategies and molecular testing to address those needs. Certain cancers can sometimes have mutations in the KRAS gene,…
-
Noosa News21 hours agoToombul Shopping Centre site thrown lifeline after Mirvac announces sale with ‘priority’ to build new retail centre
-
General22 hours agoAllegations against ex-Attorney-General Mark Dreyfus removed from Linda Reynolds action against Commonwealth
-
General10 hours agoDriver charged after fatal alleged hit-run crash at Hillier
-
Noosa News24 hours agoMirvac to sell site to Irvine Group